Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Cash from Financing Activities of -$78.5 million for Q1 2026, up 90.35% year-over-year from -$41.2 million in Q1 2025, and down 204.06% quarter-over-quarter from $75.4 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$78.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 90.35% year-over-year to -$78.5 million; the TTM figure through Mar 2026 stood at -$138.4 million (up 81.21% YoY), while the FY2025 annual figure was -$873.4 million, down 4357.07% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$78.5 million, down from $75.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $246.4 million in Q3 2024, with the low at -$813.5 million in Q1 2025.
- The 5-year median for Cash from Financing Activities is -$78.5 million (2023), against an average of -$103.9 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 1581.78% in 2022, then jumped 1011.66% in 2025.
- Jazz Pharmaceuticals' Cash from Financing Activities stood at $19.6 million in 2022, then sank by 611.87% to -$100.3 million in 2023, then surged by 91.75% to -$8.3 million in 2024, then surged by 1011.66% to $75.4 million in 2025, then tumbled by 204.06% to -$78.5 million in 2026.
- Business Quant data shows JAZZ's Cash from Financing Activities at -$78.5 million in Q1 2026, $75.4 million in Q4 2025, and -$10.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | -994.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -994.50 Mn |
| Jun 30, 2026 | -994.50 Mn |
| Mar 31, 2026 | -78.50 Mn |
| Mar 31, 2026 | -78.50 Mn |
| Dec 31, 2025 | 75.44 Mn |
| Dec 31, 2025 | 75.44 Mn |
| Sep 30, 2025 | -10.83 Mn |
| Sep 30, 2025 | -10.83 Mn |
| Jun 30, 2025 | -124.49 Mn |
| Jun 30, 2025 | -124.49 Mn |
| Mar 31, 2025 | -813.50 Mn |
| Mar 31, 2025 | -813.50 Mn |
| Dec 31, 2024 | -8.28 Mn |
| Dec 31, 2024 | -8.28 Mn |
| Sep 30, 2024 | 246.43 Mn |
| Sep 30, 2024 | 246.43 Mn |
| Jun 30, 2024 | -161.09 Mn |
| Jun 30, 2024 | -161.09 Mn |
| Mar 31, 2024 | -56.55 Mn |
| Mar 31, 2024 | -56.55 Mn |